Cadila Healthcare gains after Zydus receives EIR from USFDA
The scrip touched its fresh 52-week high of Rs 926.25 on December 28, 2016.
By ETMarkets.com | Updated:
NEW DELHI: Shares of Cadila Healthcare advanced in Wednesday's trade after Zydus Cadila received establishment inspection report from the US health regulator for its manufacturing facility in Ahmedabad, signifying a successful closure of the USFDA audit.
Following the development, the stock gained 1.09 per cent to end the session at Rs 503.35 on BSE. It opened at Rs 504.90 and touched an intraday high and low of Rs 512.90 and Rs 500.95 respectively.
In a regular statement, the company said that the Ahemadabad manufacturing unit had completed the USFDA audit from January 16, 2017 to January 24, 2017.
Promoters held 74.79 per cent stake in the company as of June 2017. For the quarter ended June 30, 2017, the company reported total revenue at 1,055.40 crore and net profit stood at 91.40 crore.
The scrip touched its fresh 52-week high of Rs 926.25 on December 28, 2016 and its 52-week low of Rs 777.50 on November 15, 2016.
Following the development, the stock gained 1.09 per cent to end the session at Rs 503.35 on BSE. It opened at Rs 504.90 and touched an intraday high and low of Rs 512.90 and Rs 500.95 respectively.
In a regular statement, the company said that the Ahemadabad manufacturing unit had completed the USFDA audit from January 16, 2017 to January 24, 2017.
Promoters held 74.79 per cent stake in the company as of June 2017. For the quarter ended June 30, 2017, the company reported total revenue at 1,055.40 crore and net profit stood at 91.40 crore.
The scrip touched its fresh 52-week high of Rs 926.25 on December 28, 2016 and its 52-week low of Rs 777.50 on November 15, 2016.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Cadila Pharma introduces vaccine for seasonal fluADVERTISEMENT
